Deborah Stephens, DO
Deborah Stephens, DO is the Director of the Chronic Lymphocytic Leukemia (CLL)/Lymphoma Program at the Huntsman Cancer Institute at the University of Utah. She completed her internal medicine residency at Cleveland Clinic and fellowship training at The Ohio State University. Dr. Stephens leads a subspecialty clinic with a focus on patients with CLL and lymphoma. Her primary research interests include developing new targeted therapies for patients with CLL and lymphoma, studying resistance to current therapies, and developing supportive therapies for complications of CLL. She is the Physician Leader of the Hematology Clinical Trials Division at Huntsman Cancer Institute and is the principal investigator on multiple clinical trials including the international principal investigator for the SWOG S1925 EVOLVE CLL Study (NCT04269902). She is an expert panelist for the National Comprehensive Cancer Network (NCCN) CLL Guidelines Panel, which establishes and published the most widely referenced guidelines for the evaluation and treatment of patients with CLL. Dr. Stephens is also a member of the medical board for the CLL Society, which is the largest patient-led CLL group in the country. The sum of Dr. Stephens's experiences demonstrates her deep commitment to improve the care of patients with CLL and lymphoma.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Innate PharmaDate added:09/22/2021Date updated:04/07/2023Relationship end date:01/27/2021
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:TG TherapeuticsDate added:09/22/2021Date updated:04/07/2023Relationship end date:02/03/2021
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AstraZenecaDate added:09/22/2021Date updated:04/07/2023Relationship end date:05/13/2021
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AbbvieDate added:09/22/2021Date updated:04/07/2023Relationship end date:06/29/2021
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:CSL BehringDate added:09/22/2021Date updated:04/07/2023Relationship end date:06/15/2021
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:CelegeneDate added:09/22/2021Date updated:04/07/2023Relationship end date:06/25/2021
-
Type of financial relationship:Grant Or ContractIneligible company:Karyopharm, Novartis, Arqule, Mingsight, JUNO, NewaveTopic:clinical research fundingDate added:09/22/2021Date updated:04/07/2023